---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-114274"
form_type: "8-K"
ticker: "ACXP"
cik: "0001736243"
company_name: "Acurx Pharmaceuticals, Inc."
filed_at: "2023-11-03T23:59:59+00:00"
generated_at: "2026-06-08T22:37:58.481405+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Acurx reports 96% clinical cure rate in Phase 2 trial of ibezapolstat for C. difficile infection

## Summary
- 96% clinical cure rate (25/26 patients) in combined Phase 2a and 2b trials of ibezapolstat.
- Ibezapolstat well tolerated; no drug-related serious adverse events; three mild GI events resolved.
- Phase 2b vancomycin-controlled segment terminated early based on high observed cure rate.
- Company plans End-of-Phase 2 FDA meeting in Q1 2024 and advancement to Phase 3.
- Additional analyses of sustained cure, microbiome, and bile acids are forthcoming.

## SEC filing metadata
- accession: 0001104659-23-114274
- form_type: 8-K
- ticker: ACXP
- cik: 0001736243
- company_name: Acurx Pharmaceuticals, Inc.
- filed_at: 2023-11-03T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1736243/000110465923114274/0001104659-23-114274-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1736243/000110465923114274/tm2329812d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-114274
- JSON: https://secwatch.observer/filing/0001104659-23-114274.json
- Plain text: https://secwatch.observer/filing/0001104659-23-114274.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.